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Although the relative contribution of different immune effector functions to clearing tissues of cytomegalo-
virus is controversial, the contribution of CD8+ T lymphocytes has generally been accepted as essential. In this
report, we show that under certain conditions the CD8+ T-lymphocyte subset can be dispensable for clearance
of cytomegalovirus. Mice depleted of the CD8+ T-lymphocyte subset eliminated infectious virus with a
clearance kinetics similar to that of normal mice. Adoptive transfer studies revealed that the limitation of virus
spread required the cooperation between the CD4+ subset and other cells. Comparison between protective
functions generated in fully immunocompetent and in CD8- mice demonstrated that elimination of the CD8+
subset before infection altered the quality of the antiviral immune response. The compensatory protective
activity gained by CD4+ cells in CD8- mice was absent in normal mice recovering from virus infection.
Human cytomegalovirus (HCMV), a member of the her-
pesvirus family, is endemic in all human populations. Similar
to other herpesvirus infections, acute HCMV infection is
followed by chronic infection or viral latency from which
reactivation can occur. Congenital HCMV infection of the
immunologically immature fetus represents the most com-
mon viral intrauterine infection, and HCMV is also the major
cause of viral morbidity and mortality in immunocompro-
mised patients. The status of the immune system dictates
whether infection is asymptomatic or leads to clinical or
even fatal disease. Since reactivation can also occur in
seropositive subjects, cellular immune mechanisms appear
to have a major role in HCMV control. Accordingly, the
activity of cytolytic T lymphocytes was found to correlate
with recovery of transplant patients from primary HCMV
infection (26). The role of CD4+ T lymphocytes and the
protective effects of antibodies are not clear. Prophylactic
administration of anti-HCMV immunoglobulin can reduce
the severity of HCMV disease and has an effect on the
incidence of HCMV pneumonitis, whereas therapeutic ap-
plication has been mainly without protective effects (41).
To study the immune mechanisms in the infected host,
infection of mice with murine cytomegalovirus (MCMV) has
been used as a suitable animal model (13). Evidence has
been provided that primed CD8+ T lymphocytes can protect
against subsequent lethal MCMV disease (24, 28, 31, 32, 34).
This protective function of the antecedent CD8+ T-lympho-
cyte activity was documented by cell transfer experiments
and by the selective activation of antiviral CD8+ T lympho-
cytes (8, 14). The experiments invariably showed that when-
ever CD8+ T lymphocytes were activated, they played a
dominant role in protection. The significance of antibody is
not clear, since prophylactic transfer of antiserum to MCMV
has protective activity, whereas immunoglobulin therapy of
established infection does not prevent viral spread (38).
Similarly, the contribution of sensitized CD4+ T lympho-
cytes is controversial (28, 36). These data show clearly that
a preceding activation of both cellular and humoral immune
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functions can contribute to protection against subsequent
primary MCMV infection or reinfection.
The relative importance of the different immune effector
mechanisms that are generated during primary infection is
not revealed by these studies. Therefore, we have started to
analyze the contribution of the CD4+ and the CD8+ T-lym-
phocyte subsets to MCMV clearance. The experimental
approach has been the depletion of lymphocyte subsets in
vivo before and during infection. We have reported recently
that mice can control acute MCMV infection in the absence
of the CD4+ subset (15). CD4- mice clear most infected
organs but develop a chronic infection confined to the
salivary glands. In the study reported here, we tested the
alternative situation. Mice were depleted of the CD8+
T-lymphocyte subset and then infected with MCMV. The
results show that recovery from acute MCMV infection can
proceed in the absence of the CD8+ T-cell subset. Although
virus clearance was almost indistinguishable between nor-
mal and CD8- mice, major differences were revealed by the
analysis of immune effector functions.
MATERIALS AND METHODS
Elimination of T-lymphocyte subsets in vivo. Female
BALB/c mice 4 to 5 weeks of age were thymectomized under
chloral hydrate anesthesia according to standard surgical
procedures. In vivo depletion of T-lymphocyte subsets was
carried out as described by Cobbold et al. (6). Depletion of
the CD8+ subset was accomplished by daily intravenous
injections of thymectomized mice (for time schedule, see
Fig. 1) with 1 mg of rat immunoglobulin G2b (IgG2b)
anti-murine CD8 monoclonal antibody (MAb) YTS 169.4 (6)
for 3 successive days. After that period, CD8+-depleted
mice were injected weekly with 0.25 mg of mouse IgG2a
anti-Lyt 2.2 (CD8) MAb 19/178 (10) throughout the experi-
ment. For depletion of CD4+ T lymphocytes, mice were
injected intravenously with 1 mg of rat IgG2b anti-mouse
CD4 MAb YTS 191.1 (6) for 3 successive days. The antibod-
ies used for in vivo treatment were enriched from ascitic
fluid by precipitation with 50% ammonium sulfate and sub-
sequent dialysis against phosphate-buffered saline. The con-
centration of specific antibody was determined by immuno-
diffusion, using rat and mouse IgG standards (15).
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Monitoring of T-cell subsets. Depletion efficacy of T-lym-
phocyte subsets in cell suspensions was tested by single-
parameter cytofluorometric analysis for the presence of the
CD4+ and CD8+ subsets as described previously (15). The
depletion efficacy of T-lymphocyte subsets after treatment
with anti-CD4 and anti-CD8 MAb in tissues was tested by
indirect immunoperoxidase staining of frozen tissue sections
as described by Hsu et al. (12).
Virus and infection conditions. The Smith strain of MCMV
(VR-194; American Type Culture Collection, Rockville,
Md.) was propagated in BALB/c mouse embryo fibroblasts
as described previously (29). Mice were infected by injection
of 2 x 105 PFU of MCMV into one hind footpad. T-cell
subset-depleted mice were infected after the third injection
of rat MAb, and recipients for the adoptive transfer were
infected 2 h after irradiation and cell transfer.
Determination of virus titers in tissues. MCMV in tissues
was quantified by plaque assay (34). The detection limit was
100 PFU of MCMV per organ homogenate. Virus titers (x
and y) were regarded as significantly different for P (x versus
y) < a = 0.05 (one sided), where P is the observed
probability value and a is a selected significance level
(Wilcoxon-Mann-Whitney exact rank sum test).
Adoptive lymphocyte transfer. The prophylactic adoptive
cell transfer was performed as described previously (34).
Recipient mice were subjected to total-body -y irradiation
with 6 Gy 2 h before cell transfer. Donor spleen lymphocytes
to be transferred were either used as nonseparated cell
suspension or enriched to a purity of more than 95% T
lymphocytes by passage through nylon-wool columns. If
necessary, T-lymphocyte subsets were depleted by treat-
ment with MAb to CD4 (9) or CD8 (10), respectively, and
complement.
Generation of cytolytic effector cells and cytolytic assay.
Splenocytes and mesenteric lymph node lymphocytes were
obtained 4 weeks after infection with MCMV. Lymphocytes
(2 x 106 cells per ml in 4-ml cultures) were restimulated in
vitro with 105 PFU of MCMV per ml and 5 x 105 stimulator
cells per ml. At day 3 of culture, 25 U of recombinant human
interleukin-2 (Sandoz Forschungsinstitut, Vienna, Austria)
was added per ml, and cultures were tested for cytolytic
activity at day 6. KD2SV cells (simian virus 40-transformed
kidney fibroblasts from B1O.D2 [H-2d] mice) were used as
target cells after incubation with a synthetic peptide contain-
ing the antigenic epitope recognized by BALB/c cytolytic T
lymphocytes (CTL) in pp89, an immediate-early-phase reg-
ulatory protein of MCMV (8, 16, 33). The cells were pulsed
with 100 ,uM of 19-mer peptide P(161-179) during the 90-min
51Cr-labeling period, and excess peptide was removed by
washing of target cells before incubation with effector cells.
A standard 3-h cytolytic assay was performed (30) with 103
target cells and graded numbers of effector cells in twofold-
dilution steps. Data represent the mean percentage of spe-
cific lysis from three replicate cultures.
Detection of virus-specific antibodies. An enzyme-linked
immunosorbent assay (ELISA) for quantifying MCMV-spe-
cific antibodies in sera by using infected mouse embryo
fibroblasts as a source of antigens was used (14). Titers were
read from the half-maximal optical density after subtraction
of values from control lysates of noninfected fibroblasts.
Tumor transplantation. A/J (H-2a)-derived sarcoma I (Sal)
tumor was propagated in ascitic form in A/J mice. Sal
expresses major histocompatibility complex (MHC) class I
antigens, including Kk, Dd and Ld, but is devoid of class II
molecules on the cell surface (7, 40). Ascites-passaged Sal
tumor cells were harvested from A/J mice 5 to 7 days after
intraperitoneal inoculation of 5 x 106 tumor cells. Cells were
washed in phosphate-buffered saline and injected (5 x 105
tumor cells) subcutaneously into the lateral thoracic skin in
thymectomized BALB/c mice. Tumor diameter was mea-
sured with a caliper in two dimensions at a 90° angle, and
tumor size is expressed as mean tumor diameter.
RESULTS
Experimental design. The experiments were designed to
study the ability of mice to control MCMV infection after
ablation of the CD8+ T-lymphocyte subset. Because even
fully immunocompetent mice require at least 6 weeks for
clearance of tissues from infectious virus and establishment
of viral latency, a protocol for efficient long-term depletion
of T-lymphocyte subsets was essential. The time schedule
for the treatments and assays is outlined in Fig. 1. In a
previous report, we described the course of MCMV infec-
tion in long-term CD4- mice (15). In that study, the state of
CD4+ subset deficiency was maintained by weekly injection
of rat MAb to murine CD4. Because of the risk of an
antiglobulin response to xenogeneic antibodies, this protocol
could not be applied to long-term depletion of CD8+ T
lymphocytes. Therefore, thymectomized mice were used to
prevent the repopulation of peripheral lymphoid organs.
Mice were first injected with MAb of rat origin on 3
consecutive days before infection with MCMV. The efficacy
of T-cell subset depletion was controlled by cytofluorometry
and immunohistology. Whereas a low number of CD8+ T
lymphocytes was still detectable in lymphoid tissues 6 weeks
after treatment of mice with rat MAb to murine CD8 alone,
the number of these residual cells was reduced to the
background level by additional weekly injection of murine
MAb to CD8 (data not shown). Functional CD8+ T-lympho-
cyte inactivation was monitored by testing the capacity to
generate MCMV-specific CTL and by testing the rejection of
an allogeneic tumor graft differing in MHC class I molecules.
Thymectomized mice were also depleted of the CD4+
T-lymphocyte subset to provide either CD4- or CD8- mice
under conditions that allow comparison between previously
published data and the results presented here. The state of
MCMV infection in immunosuppressed and control mice
was monitored by screening individual mice collected ran-
domly from the respective samples. The antiviral effect of
lymphoid cells was tested by adoptive transfer into MCMV-
infected syngeneic recipient mice that were immunodepleted
by 6 Gy of irradiation (34). This adoptive transfer regimen
was developed previously as a model for cytoimmunopro-
phylaxis of CMV disease and can be used as an in vivo assay
for estimating the strength of the T-lymphocyte-mediated
antiviral immunity generated in the donor mice (24, 28, 31,
32, 34).
Functional depletion of the CD8+ subset in vivo. Immuno-
suppressed and control mice were infected with MCMV.
None of the CD4- mice but also none of the CD8- mice
showed signs of illness or succumbed to MCMV infection.
Four weeks later, spleen cells were isolated and restimulated
with MCMV in vitro, and the generation of a CTL response
was tested (Fig. 2). CTL from both MCMV-primed immu-
nocompetent mice and CD4- mice were able to lyse KD2SV
(H-2d) fibroblast targets pulsed with synthetic peptide P(161-
179). This peptide represents the epitope recognized by CTL
in the immediate-early protein pp89, an immunodominant
antigen of MCMV recognized by antiviral CD8+ CTL (8, 14,
16, 17, 30, 33, 42). In vivo depletion of the CD8+ T-lympho-
cyte subset abolished generation of the CTL response.
J. VIROL.
 at Universitaetsbibliothek M
uenchen on O
ctober 22, 2008 
jvi.asm.org
D
ow
nloaded from
 
CYTOMEGALOVIRUS CONTROL DURING CD8+ SUBSET DEFICIENCY
CTL- generatizon
Tx Rat &CD8 Virus titer
Mouse taCD8 I
Donor V V V V v V
Immunohistology
Virus titer
Antibody titer
t
V V
2 4
Lymphocyte transfer
aCD4
or
etCDS
I
6 Gy irradiation
and infection
12 (wk)
2 (wk)
Virus titer
FIG. 1. Experimental regimen and time schedule. Thymectomy (Tx) was carried out 2 days before infection. CD8+ T lymphocytes were
eliminated by injection with rat MAb to CD8 (aCD8; V), followed by maintenance therapy with mouse MAb to CD8 (V). At various times,
mice were sacrificed for determination of virus titers in organs, for testing of CTL activities, etc. ( 4 ). Protective capacities of lymphocytes
generated in donors were tested by adoptive lymphocyte transfer. In transferred cells, subpopulations were depleted by specific MAb plus
complement. Cell transfer recipients received 6 Gy of irradiation before infection to ablate their capacity to mount a specific immune response
during the test period.
The frequency of CTL precursors to MCMV is less than 1
in 103 CD8+ T lymphocytes for the antigen tested (17, 30).
Reduction of this number by 100-fold in CD8+-subset-de-
pleted mice could make these cells difficult to detect in vitro,
KD2SV - P(161-179)
5O 3 50 3
E: T rado
FIG. 2. Absence of virus-specific CTL in mice depleted of CD8+
T lymphocytes. The cytolytic activity to the antigenic peptide
P(161-179) of the MCMV immediate-early protein pp89 is shown for
CD4-depleted (0), CD8-depleted (V), and nondepleted (0) mice.
Effector cells were spleen lymphocytes obtained 4 weeks after
MCMV infection and in vitro restimulation with MCMV for 6 days.
although they might still contribute to antiviral defense in
vivo. The number of CD8+ T cells reactive to alloantigens is
much higher than the number of cells reactive to nominal
antigens. Thus, if the elimination ofreactive CD8+ T cells was
not complete and if such residual cells, albeit not detectable as
CTL in vitro, did contribute to protection in vivo, this effect
should be much more pronounced in response to alloantigen.
The effect of CD8+ subset depletion on protective immunity
in vivo to an MHC class I-different tumor allograft was
determined (Fig. 3). Immunocompetent control mice rejected
the tumor graft by 20 days after transplantation. The progres-
sive tumor growth observed in the group of CD8- mice and
the death of these animals within 5 weeks indicated that the
depletion protocol could be used also for long-term functional
ablation of CD8+ T lymphocytes.
Clearance of infectious virus in tissues of CD8- mice. The
state of infection in T-lymphocyte-subset-depleted mice was
studied by measuring infectious virus in organs at different
times after infection. CD4- mice exhibit a delayed clearance
of the lungs and completely fail to clear the salivary glands,
in which a persistent infection is established (15). As ex-
pected, the combination of thymectomy and CD4+ subset
depletion led to the same result (Fig. 4). By contrast, there
was remarkably little difference in virus clearance between
normal and CD8- mice. Although the lungs of some mice
still contained a low titer of virus at 2 weeks postinfection
(p.i.), the virus was effectively cleared at 4 weeks p.i. in all
mice tested. No difference was detected in the clearance
kinetics of the salivary glands between immunocompetent
and CD8- mice. Previous studies have shown that the
salivary glands represent the organ that is most difficult to
clear from MCMV by the immune system (15, 21, 31, 34).
Therefore, despite the important protective effect of CD8+ T
lymphocytes, MCMV clearance can be achieved in the
absence of this subset.
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Cells from CD8- mice require the CD4+ subset for virus
clearance. Depletion of the CD4+ subset results in a marked
reduction of the virus-specific antibody response (15). When
the antibody response in thymectomized mice was tested 12
C/(8/8) weeks p.i., again the CD4- mice generated at best marginal
antibody titers, whereas the immunocompetent and the
CD8 mice had developed titers in the range of 512 to 1,024
(data not shown). Spleen cell transfer into lethally infected
recipients was used to assay and to compare the efficacy and
the effector cell specificity of antiviral immune functions
operative in normal and subset-depleted mice.
The results are documented for the spleen as an indicator
organ of recipient mice at day 14 p.i. and adoptive transfer of
(0/5) 2 x 105 cells (Fig. 5), but essentially the same results were
_____ obtained for other organs tested, such as lungs and adrenal
0 4 8 12 16 20 24 28 glands (not shown). The difference between the virus titers(about four log1o steps) seen after transfer of spleen cells
Days after tumor transplantation isolated from noninfected, immunocompetent donors andspleen cells from MCMV-primed, immunocompetent mice
3. Effect of CD8+ subset depletion on growth of an MHC as donors (Fig. 5a) is a measure of the antiviral activity
lisparate allograft. BALB/c mice were thymectomized and present in 2 x 105 immune spleen cells. It was found that
with rat MAb to murine CD8 and then for 3 weeks with cells from all three test groups (MCMV-primed immunocom-dAb to murine CD8. Sal tumor cells (5 x 105) were injected petent mice, primed CD4- mice, and primed CD8- mice)ieously. For CD8 -subset-depleted mice (A), tumor diam- limited virus spread. To investigate the contribution of the
asurements represent the means from eight mice. For CD8' and the CD4' subsets to antiviral activity, the recip-
competent control mice (0), tumor diameter measurements
t the means of five mice. The proportions of mice dying ients of cells were injected with MAb to either CD4 or CD8
surviving tumor growth are shown in parentheses. to ablate the in vivo function of the respective transferred
cell subset and also to prevent a contribution of subsets
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FIG. 4. Effect of CD8+ subset depletion on the course of MCMV infection. A comparison was made at 2, 4, and 12 weeks p.i. between
virus production in the salivary glands and lungs of nondepleted control mice and of mice depleted of either the CD8+ or CD4+ subset of T
lymphocytes. Individually scores titers (0) and median values ( ) are shown. DL, Detection limit.
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FIG. 5. Requirement of CD4+ T lymphocytes from CD8- mice
for virus clearance. Cells were obtained from donor mice 10 weeks
p.i., and 2 x 105 cells were transferred intravenously into immuno-
depleted recipient mice for in vivo assessment of antiviral activity.
Groups of recipient mice received cells from MCMV-primed donors
that were either fully immunocompetent (O) long-term CD4+ subset
depleted (aCD4), or long-term CD8+ subset depleted (aCD8). Each
group of cell recipients was then divided into three subgroups. Mice
from the subgroups got 2 mg of rat MAb YTS 191.1 and 169.4, for in
vivo depletion of CD4+ and CD8+ T lymphocytes, respectively, or
were left untreated. Shown are titers in individual recipients,
measured 2 weeks after transfer and infection (0), and median
values ( ). The control level (CL) represents the effect seen after
transfer of the same number of cells from noninfected, immunocom-
petent control donors. DL, Detection limit.
generated de novo in only sublethally irradiated recipients.
As expected, the MAb to CD8 completely eliminated the
antiviral effect of cells from CD4- mice, which depend on
the function of CD8+ T lymphocytes (Fig. Sb). Remarkably,
the same effect was seen after treatment of mice that had
received cells from immunocompetent mice (Fig. 5a), which
demonstrates the major role that CD8+ T lymphocytes play
under natural conditions during recovery from MCMV in-
fection. Table 1 shows the effect of lymphocyte subset
depletion on the antibody response to MCMV in these mice.
After ablation of the CD8+ subset, the recipients of cells
from immunocompetent mice still generated the same titer of
antibodies, but these antibodies did not mediate virus clear-
ance. Because MAb to CD8 did not abrogate the protective
effect of cells from CD8- mice (Fig. 5c), a dominant function
of residual CD8+ T lymphocytes in this test group was
unlikely.
Treatment with MAb to murine CD4 provided the appro-
priate control and showed that the elimination of CD4+ T
lymphocytes had little effect on the protective effect of cell
populations from immunocompetent (Fig. Sa) and CD4-
mice, (Fig. Sb) although this treatment abolished antibody
production in the recipients of cells from nondepleted mice
(Table 1). Treatment of recipients of cells from CD8- mice
with MAb to murine CD4, however, eliminated both the
antiviral activity (Fig. Sc) and the capacity to produce
antibodies to MCMV (Table 1). Thus, the CD8- mice harbor
TABLE 1. Requirement of the MCMV-specific antibody response
in cell transfer recipients for CD4+ T-helper lymphocytes
Determination for recipients
Cell donora Treatment No. of seropositive Antibody
(MAb in vivo) mice (n = 5) titerb
Noninfected 0 <4
Infected 5 256-512
Anti-CD4 0 <4
Anti-CD8 5 512
Infected and CD8+ 5 128-512
subset depleted
Anti-CD4 0 <4
Anti-CD8 5 128-256
The same groups as described in Fig. 5 (12 weeks after infection).
b Serum was taken from the adoptive transfer recipients 2 weeks p.i., and
MCMV-specific antibodies were determined by ELISA. Data represent the
reciprocal of the serum dilution that gave half-maximal activity.
CD4+ cells, which are essential for the limitation of viral
spread in the cell recipients. The fact that this CD4+ cell
function is not revealed in immunocompetent mice after
depletion of the CD8+ subset indicates a compensatory
function of CD4+ cells that is active only in CD8- mice.
No direct antiviral effect ofT lymphocytes from CD8- mice.
Although the CD4+ subset was essential for the antibody
response in cell recipients from all test groups, the capacity
of transferred cells to generate antiviral antibodies did not
correlate with virus clearance. In addition, only after cell
transfer from CD8- mice was the CD4+ subset essential for
antiviral activity. Collectively, these data raised the question
of a direct antiviral effector activity of the CD4+ subset in
CD8- mice. Such an effect has been described for human
CD4+ T lymphocytes after elimination of the CD8+ subset
(3). To test this possibility, the spleen cells of mice were
isolated 10 weeks p.i. and enriched for T lymphocytes. After
transfer into irradiated and MCMV-infected recipients, the
cells from noninfected donors had no activity (Fig. 6a,
column A), in contrast to T lymphocytes from primed mice
(column B). T lymphocytes from primed CD4- mice (col-
umn C) had an activity comparable to that of cells from
primed mice (compare column B with column C), whereas T
lymphocytes from primed CD8- mice (column D) were
without activity. Two conclusions were drawn. First, CD4+
T lymphocytes from CD8- mice have no direct protective
effect after transfer. The absence of a direct effector function
excluded a contribution of residual CD8+ T lymphocytes to
virus clearance by cells from CD8- mice. Second, CD4+
cells from CD8- mice must cooperate with other cells to
mediate virus clearance.
DISCUSSION
The aim of this study was to investigate whether in a state
of selective CD8+ subset deficiency the immune system can
control CMV infection and, if so, how the course of infection
(that is, the succession of acute phase, persistent phase, and
latent phase of infection) is altered in the absence of the
CD8+ subset.
We have tested the recovery of CD8- mice from MCMV
infection and report that these mice survive and are even
able to control and clear tissues of infectious MCMV. The
kinetics of virus clearance was found to be almost indistin-
guishable from that of fully immunocompetent mice. We
have reported previously that mice can effectively control
acute MCMV infection in the absence of antibodies and in
DONORS
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FIG. 6. Absence of direct antiviral activity in T lymphocytes
form CD8- mice. Nylon-wool-enriched splenic T lymphocytes (2 x
105 cells) were transferred intravenously into immunodepleted re-
cipient mice for in vivo assessment of antiviral activity. Shown are
titers in individual recipients, measured 2 weeks after cell transfer
and infection (0), and median values ( ) Columns: A, nonprimed
donors; B, nondepleted MCMV-primed donors; C, CD4+-subset-
depleted, MCMV-primed donors; D, CD8+-subset-depleted,
MCMV-primed donors.
the absence of CD4+ T-helper functions (15). The difference
that we observed between normal and CD4- mice was that
CD4- mice exhibited an altered virus clearance pattern and
developed a chronic MCMV infection of the acinar glandular
epithelial cells in salivary gland tissue. Because even a low
number of CD8+ T lymphocytes can have profound effects
on virus clearance, the new finding, namely, that CD8+ T
lymphocytes can be negligible, was somewhat disconcerting,
and it was important to rigorously exclude the putative
contribution of residual CD8+ T lymphocytes. Significant
numerical reduction of CD8+ T lymphocytes was achieved
by a combination of treatment with rat and mouse MAb
specific for the murine CD8 molecule, which led to the
efficient long-term removal of antigen-positive cells. The
functional absence of MCMV-specific CD8+ T lymphocytes
was shown in several independent assays. First, CD8- mice
did not generate CTL specific for MCMV. Second, CD8-
mice did not reject an allogeneic tumor graft. Third, whereas
protective activity in normal and in CD4- mice was associ-
ated with a direct function of CD8+ T lymphocytes, this did
not apply to T lymphocytes from CD8- mice. Fourth, the
protective function of cells from CD8- mice was destroyed
by treatment of recipients with antibody to CD4 but not to
CD8. Collectively, these data show that the CD8+ subset did
not contribute to the virus clearance in CD8- mice. Thus,
the first conclusion that can be drawn is that the course of
infection is not altered in mice deficient for the CD8+ subset.
The availability of MAb to T-lymphocyte surface mole-
cules has stimulated in vivo and in vitro analyses of antiviral
functions of T-lymphocyte subsets (43). Studies on herpes
simplex virus (HSV) (25), influenza A virus (20), lympho-
cytic choriomeningitis virus (LCMV) (1, 18, 22), ectromelia
virus (5), and MCMV (15, 28, 31, 32, 34) have consistently
stressed the importance of the contribution of CD8+ T
lymphocytes to virus clearance. However, the relative role
of each of the major T-lymphocyte subsets is apparently
quite different for each of the virus infections studied. For
instance, deletion of the CD4+ T-lymphocyte subset does
not prevent the elimination of LCMV (1, 22) or influenza A
virus (20) but causes a delayed local clearance of HSV (25)
and results in site-restricted persistent MCMV infection (15).
Even more striking are the differences in mice deficient for
the CD8+ T-lymphocyte subset: this situation leads to the
complete inability to clear LCMV (1, 22), whereas influenza
A virus-infected mice still eliminate the virus (20), and
HSV-infected mice clear the infection of the skin but de-
velop a severe infection of the nervous system (25). As
reported here, clearance of infectious MCMV in CD8- mice
is similar to that of normal mice. Thus, there is no general
assignment of a determinative role in vivo to either T-lym-
phocyte subset in recovery from viral infection. Instead, a
detailed examination is required in every virus infection
under study, and no prediction can be made even for related
viruses such as the family of herpesviruses.
At first glance, it does not appear surprising that CD8-
mice can eliminate MCMV with a clearance kinetics almost
indistinguishable from that of fully immunocompetent mice.
These mice were still able to generate antibodies to MCMV,
and the situation seen in CD8- mice could merely reflect the
residual capacity of the natural immune response after
subtraction of the important, albeit perhaps not indispens-
able, part that CD8+ T lymphocytes may play. This view is
tenable only as long as the protective principles active in
normal and in CD8- mice are not compared. Only the
characterization of cells active after transfer reveals the
difference. Fully immunocompetent mice do contain both
T-lymphocyte subsets; nevertheless, the transfer of antiviral
activity required the presence of the CD8+ subset. Elimina-
tion of the CD8+ subset did not reveal an important residual
protective capacity of the remaining CD4+ cells, although
their cooperation was essential for antibody production in
cell recipients. Thus, the result in CD8- mice, namely, that
CD4+ cells contribute to the control of virus spread, is not
identical with the antiviral activity residing in the spleen of
immunocompetent mice after MCMV infection and subse-
quent withdrawal ofCD8+ T lymphocytes. The CD4+ subset
apparently gains a major compensatory protective function
only in mice that do not contain CD8+ T lymphocytes at the
time of infection. Therefore, the second conclusion to be
drawn is that the MAb treatment has altered the quality of
the antiviral immune response.
The compensatory protective function exerted by the
CD4+ subset in CD8- mice required the cooperation of other
cells. These cells may include B cells or other cells that
respond to factors released by the CD4+ subset or both.
Antibody responses in those mice were equivalent to the
responses of immunocompetent controls whether examined
by Western immunoblot (K. Munch, unpublished data), by
ELISA, or by neutralization in the presence of complement
(data not shown). Thus, to detect differences in the antibody
response, further analyses of the isotype pattern and of the
in vivo protective activities of antisera from such mice are
required. If there are differences, we expect them to be in the
quality of the antibody response because we could not detect
a correlation between antiviral antibody titers and virus
clearance (32). Another mode of cooperation between the
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CD4+ subset and other cells could be the release of factors
resulting in the activation of nonspecific host defense mech-
anisms, as shown for an HSV-specific CD4+ T-lymphocyte
clone (19). This T-helper cell clone derived from immuno-
competent mice could protect mice from fatal infection. This
function was associated with the release of lymphokines,
including gamma interferon, which in turn increased the
virocidal activity of macrophages (35). Liberation of various
lymphokines could also activate other nonspecific host de-
fense mechanisms, such as natural killer cells, that are
thought to be important in the early defense of the host
against CMV (2, 4, 27, 37, 39).
Our new observation that the immune response following
ablation of either T-lymphocyte subset can still protect
against CMV infection may stimulate research into viral
antigens essential for stimulation of the CD4+ subset that
mediates protection, into the definition of the protective
principle resulting from the cooperation between the CD4+
subset and other cells, and into the mechanisms that regulate
MCMV control in the immunocompetent host preferentially
via the CD8+ subset. Murine CD4+ T-helper lymphocytes
can be divided into at least two types (23). At the clonal
level, these T-helper cells exhibit distinct but overlapping
functions with regard to lymphokine secretion and cell
cooperation. Data indicate that the expansion of distinct
CD4+ T-lymphocyte subsets that are correlates of the Thl
and Th2 cells defined at the clonal level in vitro can be
associated in vivo with control or progression of disease
caused by intracellular pathogens (11). A testable specula-
tion is that the long-term depletion of CD8+ T lymphocytes
alters the contribution of the two T-helper cell subsets to the
control of MCMV infection.
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